• LAST PRICE
    1.6300
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.2121%)
  • Bid / Lots
    1.5900/ 3
  • Ask / Lots
    1.6600/ 1
  • Open / Previous Close
    1.6600 / 1.6500
  • Day Range
    Low 1.5626
    High 1.6799
  • 52 Week Range
    Low 0.5171
    High 3.3197
  • Volume
    118,571
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.65
TimeVolumeNCNA
09:32 ET20631.67
09:36 ET11501.66
09:41 ET2501.65
09:52 ET5001.6153
09:57 ET24171.6755
10:06 ET1001.6783
10:10 ET10001.67
10:14 ET85001.6653
10:24 ET82121.66
10:26 ET10001.6401
10:33 ET3001.6401
10:35 ET27291.65
10:37 ET10921.65
10:42 ET34041.65
10:46 ET1001.63
10:53 ET50001.65
10:57 ET1001.65
11:06 ET7001.65
11:09 ET3001.6489
11:15 ET1001.64
11:24 ET18911.63
11:29 ET20001.63
11:40 ET1001.64
11:42 ET4001.64
11:45 ET1061.64
11:51 ET1001.645
11:58 ET20001.64
12:07 ET1001.64
12:34 ET2831.63
12:36 ET3171.63
12:39 ET75611.63
12:43 ET1001.61
01:08 ET8001.6213
01:19 ET10001.62
01:21 ET30001.6399
01:26 ET21031.5626
01:28 ET80001.5701
01:39 ET6001.585
01:42 ET27001.58
01:51 ET7401.58
01:53 ET308981.58
02:15 ET2001.61
02:24 ET10001.6284
02:29 ET2001.63
02:45 ET6001.62
02:56 ET2001.62
03:03 ET5401.615
03:50 ET10251.6118
03:59 ET4061.63
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNCNA
NuCana PLC
80.9M
-1.8x
---
United StatesANEB
Anebulo Pharmaceuticals Inc
97.8M
-2.7x
---
United StatesANVS
Annovis Bio Inc
100.3M
-5.8x
---
United StatesPYXS
Pyxis Oncology Inc
96.8M
-1.3x
---
United StatesMGTA
Magenta Therapeutics Inc
98.9M
-1.4x
---
United StatesKNWN
Know Labs Inc
95.5M
-3.2x
---
As of 2022-08-15

Company Information

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The Company's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.

Contact Information

Headquarters
Lochside House, 3 Lochside WayEDINBURGH, United Kingdom EH12 9DT
Phone
131-248-3660
Fax
131-248-3001

Executives

Non-Executive Independent Chairman of the Board
Andrew Kay
Chief Executive Officer, Co-Founder, Executive Director
Hugh Griffith
Chief Financial Officer
Donald Munoz
Chief Medical Officer
Jeffrey Bloss
Head - Translational Studies
David Harrison

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$80.9M
Revenue (TTM)
$0.00
Shares Outstanding
52.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.21
EPS
$-0.92
Book Value
$1.54
P/E Ratio
-1.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.